This video examines phase II results of a single-arm trial that tested checkpoint inhibition plus the IDO–pathway inhibitor indoximod in patients with melanoma.
Yousef N. Zakharia, MD
Advertisement
Articles by Yousef N. Zakharia, MD
Advertisement
Latest Updated Articles
Adding Indoximod to Pembrolizumab Improved Response Rate in Advanced MelanomaPublished: April 5th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
3
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5
